European Archives - Page 1153 of 1224 - European Medical Journal

Interview with Prof. Iain McInnes at EULAR 2015

Interview with Prof. Iain McInnes at the European League Against Rheumatism (EULAR) 2015 discussing his research on spondyloarthritis.

EMJ

PERSIST-2: Phase 3 trial of pacritinib versus best available therapy for myelofibrosis

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, of Mayo Clinic, Arizona, TX, discusses the ongoing PERSIST-2…

EMJ

Emerging immunotherapies for kidney cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles. MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University…

EMJ

Phase 3 COMBI-d trial of dabrafenib plus trametinib in metastatic

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute, London, UK…

EMJ

ARAMIS: Phase 3 trial of ODM-201 for high-risk non-metastatic castration-resistant prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Villejuif, France…

EMJ

Phase 1b trial of idelalisib in combination with chemoimmunotherapy for relapsed/refractory CLL

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, discusses the results of a phase 1b trial that…

EMJ

PALOMA-3: Palbociclib plus fulvestrant in hormone receptor-positive advanced breast cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill, NC…

EMJ

Immune responses and clinical outcomes in STAND trial of sipuleucel-T and ADT in prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses…

EMJ

ELOQUENT-2: Elotuzumab for relapsed/refractory multiple myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of…

EMJ

Phase 2 trial of brentuximab vedotin plus AVD for limited-stage Hodgkin lymphoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center…